马翔,王宝珠,马依彤

• 1:新疆医科大学第一附属医院(第一临床医学院)

摘要(Abstract)：

心血管瓣膜疾病介入治疗方兴未艾，经导管主动脉瓣置换术引领瓣膜介入领域的发展。在过去的一年里，心血管瓣膜疾病领域的临床研究取得了令人瞩目的丰硕成果。加之科创成果的更迭，对于瓣膜疾病介入适应证的拓展、新型瓣膜材料的研发均起到了重要作用。本文从瓣膜疾病治疗相关策略、器械、技术以及患者的管理理念等方面向大家介绍和总结。

关键词(KeyWords)： 瓣膜病;介入治疗;展望

Abstract:

Keywords:

基金项目(Foundation): 心血管疾病个体化精准诊疗体系构建关键技术及优化策略研究项目（2022B03022）

作者(Author): 马翔,王宝珠,马依彤

参考文献(References)：

• [1] Forrest JK, Deeb GM, Yakubov SJ, et al. 2-year outcomes after transcatheter versus surgical aortic valve replacement in low-risk patients[J]. J Am Coll Cardiol, 2022, 79(9):882-896. DOI:10.1016/j.jacc.2021.11.062.
• [2] Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/E A CTS guidelines for the management of valvular heart disease:developed by the task force for the management of valvular heart disease of the European Society of Cardiology(ESC)and the European Association for Cardio-Thoracic Surgery(EACTS)[J].Rev Esp Cardiol(Engl Ed),2022,75(6):524. DOI:10.1016/j.rec.2022.05.006.
• [3] Van Belle E, Vincent F, Labreuche J, et al. Balloon-expandable versus self-expanding transcatheter aortic valve replacement:a propensity-matched comparison f rom the FRANCE-TAVI registry[J]. Circulation, 2020, 141(4):243-259. DOI:10.1161/CIRCULATIONAHA.119.043785.
• [4] Landes U, Sathananthan J, Witberg G, et al. Transcatheter replacement of transcatheter versus surgically implanted aortic valve bioprostheses[J]. J Am Coll Cardiol, 2021, 77(1):1-14. DOI:10.1016/j.jacc.2020.10.053.
• [5] Pibarot P, Salaun E, Dahou A, et al. Echocardiographic results of transcatheter versus surgical aortic valve replacement in low-risk patients:the PARTNER 3 trial[J]. Circulation, 2020, 141(19):1527-1537. DOI:10.1161/CIRCULATIONAHA.119.044574.
• [6] Pibarot P, Ternacle J, Jaber WA, et al. Structural deterioration of transcatheter versus surgical aortic valve bioprostheses in the PARTNER-2 trial[J]. J Am Coll Cardiol, 2020, 76(16):1830-1843. DOI:10.1016/j.jacc.2020.08.049.
• [7] Lanz J, Reardon MJ, Pilgrim T, et al. Incidence and outcomes of infective endocarditis after transcatheter or surgical aortic valve replacement[J]. J Am Heart Assoc, 2021, 10(19):e020368. DOI:10.1161/JAHA.120.020368.
• [8] Costa G, Pilgrim T, Amat Santos IJ, et al. Management of myocardial revascularization in patients with stable coronary artery disease undergoing transcatheter aortic valve implantation[J].Circ Cardiovasc Interv, 2022, 15(12):e012417. DOI:10.1161/CIRCINTERVENTIONS.122.012417.
• [9] Mas-Peiro S, Faerber G, Bon D, et al. Propensity matched comparison of TAVI and SAVR in intermediate-risk patients with severe aortic stenosis and moderate-to-severe chronic kidney disease:a subgroup analysis from the German Aortic Valve Registry[J].Clinical Research in Cardiology, 2022, 111(12):1387-1395. DOI:10.1007/s00392-022-02083-2.
• [10] Rahmani B, Tzamtzis S, Sheridan R, et al. In vitro hydrodynamic assessment of a new transcatheter heart valve concept(the TRISKELE)[J]. J Cardiovasc Transl Res, 2017, 10(2):104-115.DOI:10.1007/s12265-016-9722-0.
• [11] Kapadia S R, Makkar R, Leon M, et al. Cerebral embolic protection during transcatheter aortic-valve replacement[J]. N Engl J Med, 2022, 387(14):1253-1263. DOI:10.1056/NEJMoa2204961.
• [12] Hawkins RB, Downs EA, Johnston LE, et al. Impact of transcatheter technology on surgical aortic valve replacement volume, outcomes, and cost[J]. Ann Thorac Surg, 2017, 103(6):1815-1823. DOI:10.1016/j.athoracsur.2017.02.039.
• [13] Reynolds MR, Magnuson EA, Wang K, et al. Health-related quality of life after transcatheter or surgical aortic valve replacement in high-risk patients with severe aortic stenosis:results from the PARTNER(placement of aortic transcatheter valve)trial(Cohort A)[J]. J Am Coll Cardiol, 2012, 60(6):548-558. DOI:10.1016/j.jacc.2012.03.075.
• [14] Strange JE, Sindet-Pedersen C, Gislason GH, et al. Temporal trends in utilization of transcatheter aortic valve replacement and patient characteristics:a nationwide study[J]. Am Heart J, 2022, 243:140-146. DOI:10.1016/j.ahj.2021.09.010.
• [15] Xiong TY, Ali WB, Feng Y, et al. Transcatheter aortic valve implantation in patients with bicuspid valve morphology:a roadmap towards standardization[J]. Nat Rev Cardiol, 2022:20(1):52-67.DOI:10.1038/s41569-022-00734-5.
• [16]中华医学会心血管病学分会，中华心血管病杂志编辑委员会.经导管主动脉瓣植入术后抗血栓治疗中国专家共识[J].中华心血管病杂志，2022,50(2):117-131. DOI:10.3760/cma.j.cn112148-20210721-00608.
• [17]经导管主动脉瓣置换术流程优化共识专家组.经导管主动脉瓣置换术（TAVR）流程优化专家共识2022版[J].中华急诊医学杂志，2022,31(2):154-160. DOI:10.3760/cma.j.issn.1671-0282.2022.02.004.
• [18] Goel k. COAPT PAS:1 years outcomes from 5000 patients. ESC 2022.
• [19] Shah N, Madhavan MV, Gray WA, et al. Prediction of death or HF hospitalization in patients with severe FMR:the COAPT risk score[J].JACC Cardiovasc Interv, 2022, 15(19):1893-1905. DOI:10.1016/j.jcin.2022.08.005.
• [20] Shuvy M, von Bardeleben RS, Grasso C, et al. Safety and efficacy of MitraClip in acutely ill(NYHA ClassⅣ)patients with mitral regurgitation:results f rom the global EXPAND study[J]. ESC Heart Fail, 2023. DOI:10.1002/ehf 2.14273.Online ahead of print.
• [21] Rubbio AP, Testa L, Grasso C, et al. Transcatheter edge-to-edge mitral valve repair in atrial functional mitral regurgitation:insights from the multi-center MITRA-TUNE registry[J]. Int J Cardiol,2022, 349:39-45. DOI:10.1016/j.ijcard.2021.11.027.
• [22] Godino C, MunafòA, Scotti A, et al. MitraClip in secondary mitral regurgitation as a bridge to heart transplantation:1-year outcomes from the International MitraBridge Registry[J]. J Heart Lung Transplant, 2020, 39(12):1353-1362. DOI:10.1016/j.healun.2020.09.005.
• [23] Simard T, Vemulapalli S, Jung RG, et al. Transcatheter edge-toedge mitral valve repair in patients with severe mitral regurgitation and cardiogenic shock[J]. J Am Coll Cardiol, 2022, 80(22):2072-2084. DOI:10.1016/j.jacc.2022.09.006.
• [24] Chakravarty T, Makar M, Patel D, et al. Transcatheter edge-toedge mitral valve repair with the MitraClip G4 system[J]. JACC Cardiovasc Interv, 2020, 13(20):2402-2414. DOI:10.1016/j.jcin.2020.06.053.
• [25] Lim DS, Smith RL, Gillam LD, et al. Randomized comparison of transcatheter edge-to-edge repair for degenerative mitral regurgitation in prohibitive surgical risk patients[J]. JACC Cardiovasc Interv, 2022, 15(24):2523-2536. DOI:10.1016/j.jcin.2022.09.005.
• [26] Zahr F, Song HK, Chadderdon SM, et al. 30-Day outcomes following transfemoral transseptal transcatheter mitral valve replacement:intrepid TMVR early feasibility study results[J].JACC Cardiovasc Interv, 2022, 15(1):80-89. DOI:10.1016/j.jcin.2021.10.018.
• [27] Pan W, Zhou D, Wu Y, et al. First-in-human results of a novel userfriendly transcatheter edge-to-edge mitral valve repair device[J].JACC Cardiovasc Interv,2019, 12(23):2441-2443. DOI:10.1016/j.jcin.2019.05.043.
• [28] Raposeiras-Roubin S, Adamo M, Freixa X, et al. A score to assess mortality after percutaneous mitral valve repair[J]. J Am Coll Cardiol, 2022, 79(6):562-573. DOI:10.1016/j.jacc.2021.11.041.
• [29] Eleid MF, Wang DD, Pursnani A, et al. 2-Year outcomes of transcatheter mitral valve replacement in patients with annular calcification, rings, and bioprostheses[J]. J Am Coll Cardiol,2022, 80(23):2171-2183. DOI:10.1016/j.jacc.2022.09.037.
• [30]中国医师协会超声分会超声心动图专业委员会，中国医师协会心血管内科医师分会结构性心脏病学组.二尖瓣经导管缘对缘修复的超声心动图操作规范中国专家共识[J].中国介入心脏病学杂志，2022,30(10):721-733. DOI:10.3969/j.issn.1004-8812.2022.10.001.
• [31]中华医学会心血管病学分会.经导管二尖瓣缘对缘修复术的中国专家共识[J].中华心血管病杂志，2022,50(9):853-863. DOI:10.3760/cma.j.cn112148-20211212-01067.
• [32] Fam NP, von Bardeleben RS, Hensey M, et al. Transfemoral transcatheter tricuspid valve replacement with the EVOQUE system:a multicenter, observational, first-in-human experience[J].JACC Cardiovasc Interv, 2021, 14(5):501-511. DOI:10.1016/j.jcin.2020.11.045. Epub 2021 Feb 10.
• [33] Webb JG, Chuang A, Meier D, et al. Transcatheter tricuspid valve replacement with the EVOQUE system:1-year outcomes of a m ulticenter, f irst-in-h uman experience[J]. JACC Cardiovasc Interv, 2022, 15(5):481-491. DOI:10.1016/j.jcin.2022.01.280.